In conclusion, our study confirms lower BAFF serum levels in AChRAb( +) but also AChRAb(–)MuSK(–) MG patients treated with CS—the question whether this effect is long-term and reflected in clinical status of patient remains open. The gene discussed is MUSK; the disease is myasthenia gravis.